Becton, Dickinson and Co ((BDX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Becton, Dickinson and Company (BDX) is currently conducting a clinical study titled ‘BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study’. The primary objective of this study is to gather safety and performance data on the BD Prevue(TM) II Peripheral Vascular Access System with Cue(TM) Needle Tracking Technology. This data will support regional registrations, such as the EU Medical Device Regulation (MDR), and help identify any unforeseen residual risks.
The study focuses on the BD Prevue(TM) II, a device used for ultrasound-guided peripheral intravenous catheter (USGPIV) placement. This technology aims to assist healthcare providers in accurately placing IV catheters using real-time ultrasound visualization, thereby improving the safety and effectiveness of the procedure.
This observational study follows a case-only model with a prospective time perspective. It involves recruiting patients who require IV catheter placement in a hospital setting, using the BD Prevue(TM) II system as part of their clinical care.
The study began on March 28, 2025, with its primary completion date yet to be determined. The latest update was submitted on July 2, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential findings that could impact regulatory approvals and market entry.
The outcome of this study could significantly influence BDX’s stock performance and investor sentiment. Positive results may strengthen BDX’s position in the medical device market, particularly in the vascular access segment, potentially impacting competitors who are also innovating in this space.
The study is ongoing, and further details are available on the ClinicalTrials portal.